Tyler J Alban

List of Publications by Year
in descending order

22 papers	1,005 citations	623188 14 h-index	752256 20 g-index
30 all docs	30 docs citations	30 times ranked	1919 citing authors

#	Article	IF	Citations
1	Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression. Cell Stem Cell, 2017, 20, 450-461.e4.	5.2	147
2	Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner. Cancer Discovery, 2020, 10, 1210-1225.	7.7	138
3	Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight, 2018, 3, .	2.3	137
4	Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression. Frontiers in Immunology, 2020, 11, 1191.	2.2	92
5	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight, 2019, 4, .	2.3	82
6	Stromal Versican Regulates Tumor Growth by Promoting Angiogenesis. Scientific Reports, 2017, 7, 17225.	1.6	63
7	Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nature Communications, 2018, 9, 578.	5.8	60
8	ADAMDEC1 Maintains a Growth Factor Signaling Loop in Cancer Stem Cells. Cancer Discovery, 2019, 9, 1574-1589.	7.7	59
9	Increased incidence of venous thromboembolism with cancer immunotherapy. Med, 2021, 2, 423-434.e3.	2.2	46
10	New Advances and Challenges of Targeting Cancer Stem Cells. Cancer Research, 2017, 77, 5222-5227.	0.4	28
11	Development of a Cx46 Targeting Strategy for Cancer Stem Cells. Cell Reports, 2019, 27, 1062-1072.e5.	2.9	27
12	JAM-A functions as a female microglial tumor suppressor in glioblastoma. Neuro-Oncology, 2020, 22, 1591-1601.	0.6	26
13	Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cells. Cell Death and Disease, 2020, 11, 152.	2.7	23
14	Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. Clinical Cancer Research, 2021, 27, 2038-2049.	3.2	22
15	Immunotherapy biomarkers: the long and winding road. Nature Reviews Clinical Oncology, 2021, 18, 323-324.	12.5	14
16	Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles. Scientific Reports, 2020, 10, 18848.	1.6	10
17	Bazedoxifene inhibits sustained STAT3 activation and increases survival in GBM. Translational Oncology, 2021, 14, 101192.	1.7	8
18	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. Neoplasia, 2022, 28, 100790.	2.3	5

#	Article	IF	Citations
19	Comparing and Contrasting the Effects of Drosophila Condensin II Subunit dCAP-D3 Overexpression and Depletion in Vivo. Genetics, 2018, 210, 531-546.	1.2	2
20	Development of a Cx46 Targeting Strategy for Cancer Stem Cells. SSRN Electronic Journal, 0, , .	0.4	1
21	High-Dimensional Analysis of Circulating and Tissue-Derived Myeloid-Derived Suppressor Cells from Patients with Glioblastoma. Methods in Molecular Biology, 2021, 2236, 157-175.	0.4	1
22	ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi12-vi13.	0.6	0